MARTA ALONSO to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications MARTA ALONSO has written about Xenograft Model Antitumor Assays.
Connection Strength
0.279
-
ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res. 2007 Sep 01; 67(17):8255-63.
Score: 0.042
-
Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther. 2007 Sep; 15(9):1607-15.
Score: 0.041
-
Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory. Mol Cancer Ther. 2022 03 01; 21(3):471-480.
Score: 0.028
-
Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. Clin Cancer Res. 2021 03 15; 27(6):1807-1820.
Score: 0.026
-
The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models. Sci Rep. 2019 10 07; 9(1):14368.
Score: 0.024
-
Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clin Cancer Res. 2019 11 15; 25(22):6801-6814.
Score: 0.024
-
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019 05 28; 10(1):2235.
Score: 0.023
-
Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01. PLoS One. 2016; 11(1):e0147211.
Score: 0.019
-
The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. Clin Cancer Res. 2016 05 01; 22(9):2217-25.
Score: 0.018
-
The oncolytic adenovirus ?24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity. J Bone Miner Res. 2014 Oct; 29(10):2287-96.
Score: 0.017
-
Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget. 2014 Apr 30; 5(8):2208-20.
Score: 0.016